Isabella Ciccone, MPH

Although the magnitude of the association for smoking, atrial fibrillation and left ventricular hypertrophy did not decrease, their importance for stroke risk likely increases with age.

Data showed improvement in excessive daytime sleepiness and cataplexy frequency for children with narcolepsy on pitolisant.

A meta-analysis displayed a small magnitude of pooled effect estimates for the studied skip-amenable mutation classes in Duchenne muscular dystrophy at 1 year follow up.

Investigators concluded that the therapeutic effectiveness of antiparkinsonian medications is short and limited for intolerable abdominal pain.

In honor of International Epilepsy Day, held February 13, 2023, get caught up on some of the latest news in epilepsy as the NeurologyLive® team shares some of our data updates and expert insights.

Caregivers of patients with advancing PD were more likely to spend more hours caring per day and had a higher self-perceived burden, compared with caregivers for patients with early PD.

Blood pressure medications may not be safe or effective to use for lowering systolic blood pressure following endovascular treatment for acute ischemic stroke.

Patients with noncardioembolic ischemic stroke do not typically monitor post-stroke longterm to detect atrial fibrillation although findings from a trial follow-up suggest otherwise.

Results from a recent study suggest that greater cumulative exposure to estrogen throughout a woman’s lifespan could increase her risk of stroke.

Descartes-08, an investigational autologous RNA-engineered chimeric antigen receptor T-cell therapy (rCAR-T) has been dosed with the first participant in phase 2b randomized controlled trial.

A web-based survey of Korean neurologists interested in narcolepsy presented their concerns with using the multiple sleep latency test, noting that it may lead to ambiguous results due to accompanying sleep disorders like sleep apnea.

The clinical psychologist from Ayer Neuroscience Institute at Hartford Healthcare Headache Center shared some highlights from her recently published survey study on migraine treatment during pregnancy.

In celebration of Women’s Physician Day, held February 3, 2022, take a look back at some of the latest conversations and news that were driven and delivered by women in neurology.

Majority of women’s healthcare providers reported in a survey feeling either somewhat or very comfortable with recommending or continuing acute treatments for pregnant patients with migraine.

Recruitment has begun for REGENXBIO's AFFINITY BEYOND clinical trial assessing the prevalence of AAV8 antibodies in male patients with Duchenne muscular dystrophy.

Branaplam, an mRNA splicing modifier, joins the many unsuccessful agents for Huntington disease as biopharma continues to be challenged with trial holds and failures.

A cross-sectional and longitudinal comparative analysis suggests a subclinical neurodegenerative process may occur in MOG antibody disease based on a distinct pattern of brain atrophy.

Results from the CIRCLES cohort demonstrated a significant association in relapse patterns and disease phenotype for patients with NMOSD who change treatment.

Li-Huei Tsai, PhD, director, the Picower Institute for Learning and Memory at Massachusetts Institute of Technology, discussed research results using gamma frequency sensory stimulation in Alzheimer disease.

Take a look at 5 of the most-anticipated FDA pending approvals expected in 2023 that neurological researchers and clinicians should keep an eye out on.

According to a medical records analysis, patients with late onset NMOSD experience transverse myelitis more frequently at disease onset in comparison with early onset NMOSD.

Michael Pencina, PhD, vice dean for data science at Duke University School of Medicine spoke about assessing the differences in stroke risk with Americans using algorithms.

Michelle Chen, PhD, a neuropsychologist at Rutgers University, talked about the motivations behind her most recent published study on incorporating keystroke dynamics in MS cognition.

The FDA lifted its clinical hold on Astellas Pharma's FORTIS trial for evaluating AT845 in adults with late-onset Pompe disease.

In the letter, the FDA specifically required that Eli Lilly provide data from at least 100 patients who received a minimum of 12 months of continuous treatment with donanemab.

A systematic review revealed inconsistencies in the literature for assessing subjective cognitive complaints in cognitively normal patients with Parkinson disease.

Results from on ongoing phase 1 trial showed a favorable safety profile with CT103A in patients with NMOSD.

Sharon Cohen, MD, FRCPC, provided an investigator perspective on the use of lecanemab for patients with Alzheimer disease and what the clinician community can take away from the trials.

Glymphatic function demonstrated no significant difference in patients with type 1 and type 2 narcolepsy in comparison with healthy controls.

Sharon Cohen, MD, FRCPC, offered her insight on the significance of the lecanemab approval and what it means for patients with Alzheimer disease.